SCHEMBL6609432

SCHEMBL6609432

COc1ccc(S(=O)(=O)N(Cc2ccccc2N)OC(=O)CCO)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 7/20 0.48
NFE2L2 Q16236 5/20 0.47
TAS2R14 Q9NYV8 5/20 0.42
PTGES O14684 1/20 0.42
TAS2R8 Q9NYW2 1/20 0.42
CXCR3 P49682 1/20 0.42
MMP8 P22894 3/20 0.41
MMP13 P45452 3/20 0.41
MMP1 P03956 2/20 0.41
MMP2 P08253 2/20 0.41
CA2 P00918 1/20 0.41
MMP9 P14780 1/20 0.41
BMP1 P13497 1/20 0.41
NCOR2 Q9Y618 2/20 0.40
POLB P06746 1/20 0.40
GRK2 P25098 1/20 0.40
PPARG P37231 1/20 0.40
KMT2A Q03164 1/20 0.40
CTDSP1 Q9GZU7 1/20 0.40
NR2E3 Q9Y5X4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6607579 0.76 KEAP1 (0.67) KEAP1NFE2L2TAS2R14PTGESTAS2R8
SCHEMBL6609624 0.75 KEAP1 (0.84) KEAP1NFE2L2TAS2R14PTGESTAS2R8
SCHEMBL6608765 0.74 KEAP1 (0.64) KEAP1NFE2L2TAS2R14MMP8MMP13
SCHEMBL5655796 0.73 KEAP1 (0.56) KEAP1NFE2L2TAS2R14MMP8MMP13
SCHEMBL6609435 0.72 KEAP1 (0.60) KEAP1NFE2L2TAS2R14MMP8MMP13
SCHEMBL13570528 0.68 MMP9 (0.55) KEAP1NFE2L2CXCR3MMP13MMP1
SCHEMBL23542488 0.66 KMT2A (0.59) KMT2AHDAC3HDAC1
SCHEMBL22251960 0.65 KEAP1 (1.00) KEAP1NFE2L2TAS2R14PTGESTAS2R8
SCHEMBL8843349 0.65 BMP1 (0.58) KEAP1NFE2L2TAS2R14PTGESTAS2R8
SCHEMBL8023076 0.65 KEAP1 (0.46) KEAP1NFE2L2MMP8MMP13MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1147095-B1 2, 3, 4, 5-TETRAHYDRO-1H-[1, 4] BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS WYETH CORP (US) 2004-08-11 EP disclosed
US-6544984-B1 Treating disease conditions mediated by matrix metalloproteinases and TACE, such as tumor growth, osteoarthritis, rheumatoid arthritis and degenerative cartilage loss. AMERICAN CYANAMID COMPANY 2003-04-08 US disclosed
EP-1147095-A1 2, 3, 4, 5-TETRAHYDRO-1H-[1, 4] BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS American Cyanamid Company (US) 2001-10-24 EP disclosed
EP-1051407-A1 2,3,4,5-TETRAHYDRO-1H-[1,4]-BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS American Cyanamid Company (US) 2000-11-15 EP disclosed
WO-2000044730-A1 2,3,4,5-TETRAHYDRO-1H-[1,4]BENZODIAZEPINE-3-HYDROXAMIC ACID AS MATRIX METALLOPROTEINASE INHIBITORS AMERICAN CYANAMID COMPANY (US) 2000-08-03 WO disclosed
US-6071903-A ENZYME INHIBITORS OF MATRIX METALLOPROTEINASES (MMPS); ANTITUMOR,-CARCINOGENIC AND -ARTHRITIC AGENTS; OSTEOARTHRITIS; RHEUMATOID DISEASES; DEGENERATIVE CARTILAGE LOSS; LONG-ACTING, ORALLY BIOAVAILABLE NONPEPTIDE INHIBITORS AMERICAN CYANAMID COMPANY (US) 2000-06-06 US disclosed
WO-1999037625-A1 2,3,4,5-TETRAHYDRO-1H-[1,4]-BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS AMERICAN CYANAMID COMPANY (US) 1999-07-29 WO disclosed